Tuomas Knowles
Fondateur chez Fluidic Analytics Ltd.
Profil
Tuomas Knowles is the founder of Fluidic Analytics Ltd., where he currently holds the title of Director & Chief Scientific Officer since 2015.
He is also the founder of Wavebreak Therapeutics Ltd., founded in 2016.
Dr. Knowles is also the founder of Transition Bio, Inc. Dr. Knowles obtained a doctorate degree from the University of Cambridge.
Postes actifs de Tuomas Knowles
| Sociétés | Poste | Début |
|---|---|---|
Fluidic Analytics Ltd.
 Fluidic Analytics Ltd. BiotechnologyHealth Technology Fluidic Analytics Ltd. develops proprietary technology to characterize proteins. The company was founded by Tuomas Knowles in 2013 and is headquartered in Cambridge, the United Kingdom. | Fondateur | 17/10/2013 |
Transition Bio, Inc.
 Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Fondateur | - |
Anciens postes connus de Tuomas Knowles
| Sociétés | Poste | Fin |
|---|---|---|
Wavebreak Therapeutics Ltd.
 Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Fondateur | - |
Formation de Tuomas Knowles
| University of Cambridge | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Fluidic Analytics Ltd.
Fluidic Analytics Ltd. BiotechnologyHealth Technology Fluidic Analytics Ltd. develops proprietary technology to characterize proteins. The company was founded by Tuomas Knowles in 2013 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Transition Bio, Inc.
Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Health Technology |